Anbio Biotechnology Announces IPO Details

Ticker: NNNN · Form: 6-K · Filed: Feb 21, 2025 · CIK: 1982708

Anbio Biotechnology 6-K Filing Summary
FieldDetail
CompanyAnbio Biotechnology (NNNN)
Form Type6-K
Filed DateFeb 21, 2025
Risk Levelmedium
Sentimentneutral

Sentiment: neutral

Topics: ipo, underwriting-agreement, shares

TL;DR

Anbio Biotech is selling 1.6M shares in an IPO to AC Sunshine Securities.

AI Summary

Anbio Biotechnology, a Cayman Islands exempted company, announced on February 18, 2025, its initial public offering (IPO). The company agreed to sell 1,600,000 Class A ordinary shares at a par value of $0.0001 per share to AC Sunshine Securities LLC., acting as the representative of the underwriters.

Why It Matters

This filing details the terms of Anbio Biotechnology's initial public offering, providing insight into the company's strategy for raising capital and expanding its market presence.

Risk Assessment

Risk Level: medium — The company is undergoing an IPO, which inherently carries risks related to market reception and valuation, and the filing does not provide extensive financial details beyond the share offering.

Key Numbers

  • 1,600,000 — Class A Ordinary Shares (Number of shares to be sold in the IPO)

Key Players & Entities

  • Anbio Biotechnology (company) — Filer of the report and issuer of shares
  • AC Sunshine Securities LLC. (company) — Representative of the underwriters for the IPO
  • 1,600,000 (dollar_amount) — Number of Class A ordinary shares to be sold in the IPO
  • February 18, 2025 (date) — Date of the underwriting agreement

FAQ

What is the total number of Class A ordinary shares Anbio Biotechnology has agreed to sell in its IPO?

Anbio Biotechnology has agreed to sell an aggregate of 1,600,000 Class A ordinary shares.

Who is the representative of the underwriters for Anbio Biotechnology's IPO?

AC Sunshine Securities LLC. is the representative of the underwriters.

On what date was the underwriting agreement for the IPO entered into?

The underwriting agreement was entered into on February 18, 2025.

What is the par value of the Class A ordinary shares being offered?

The par value of the Class A ordinary shares is $0.0001 per share.

What type of company is Anbio Biotechnology?

Anbio Biotechnology is a Cayman Islands exempted company.

Filing Details

This Form 6-K (Form 6-K) was filed with the SEC on February 21, 2025 regarding Anbio Biotechnology (NNNN).

View full filing on EDGAR

View Full Filing

View this 6-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.